RxDoctor Payments Data

Lindsay Scholl, NP

Family · Denver, CONPI 1265078919

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 20 payments — averaging $86.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$310
  • United Therapeutics Corporation$250
  • Bayer$210
  • Boston Scientific$155
  • Cvrx, Inc.$142
  • Heartflow, Inc.$130
  • plus $537 from 7 others

What the payments were for

  • Food & beverage$1,68097%
  • Education$543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$46,953
Medicare patients
169
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$66,318
EntrestoSacubitril/Valsartan31$33,074
JardianceEmpagliflozin22$25,946
Repatha SyringeEvolocumab29$20,739
Bumetanide31$2,574
Potassium Chloride88$1,700
Losartan Potassium114$1,454
Rosuvastatin Calcium65$1,083
Metoprolol Succinate45$1,047
Midodrine Hcl13$1,034
Atorvastatin Calcium72$764
Torsemide24$711
Ezetimibe25$706
Amlodipine Besylate79$686
Spironolactone93$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$66,31859 claims
NovartisEntresto$18$33,07431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.

Other family in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →